SPECIAL NOTICE
99 -- Assay Portal - Maintain and Enhance the Existing Assay Portal
- Notice Date
- 1/31/2023 6:50:21 AM
- Notice Type
- Special Notice
- NAICS
- 541714
— Research and Development in Biotechnology (except Nanobiotechnology)
- Contracting Office
- NIH NCI Bethesda MD 20892 USA
- ZIP Code
- 20892
- Response Due
- 3/28/2023 12:00:00 PM
- Archive Date
- 04/28/2023
- Point of Contact
- Jo Brown, Phone: 3018465720
- E-Mail Address
-
jo.brown@nih.gov
(jo.brown@nih.gov)
- Description
- The CPTAC Assay Portal contains analytically validated assays and standard operating protocols that can be used to compare results.� This, in turn, provides a common ground for clinicians, systems biologists and analytical chemists to facilitate widespread adoption of targeted proteomic assays, such as mass spectrometry (MS)-based assays, by disseminating SOPs, reagents and assay characterization data. The goal of this project is to maintain and enhance the CPTAC Assay Portal. Objectives:� The objectives of the Assay Portal are (1) to widely disseminate highly characterized proteomic assays to the global research community, with access to SOPs, and assay characterization/validation data; (2) to bring together biologists seeking to ask hypothesis-driven questions about the proteome they study with analytical chemists equipped to perform targeted proteomic assays. The scope of this Statement of Work (SOW) is to operate, maintain and improve the existing CPTAC Assay Portal. CPTAC Assay Portal has been a Production database for over 6 years and will continue to operate, maintain, and integrate new data. The Assay Portal will maintain appropriate linkages to relevant antibodies in the Antibody Portal, �Skyline, Panorama and MSInspector that are integrated into the portal and interoperability with the NCI CRDC.� The Assay portal has integrations to CPTAC Antibody Portal that must be preserved. Background Information:� Leidos Biomedical Research, Inc. (Leidos Biomed), a subsidiary of Leidos Corporation, a Delaware corporation with offices in Frederick, MD is the Operations and Technical Support (OTS) contractor for the National Cancer Institute at Frederick.� The effort to be performed will be part of Leidos Biomed�s Prime Contract 75N91019D00024 that has been issued by the National Cancer Institute, National Institutes of Health, Frederick, MD. Leidos Biomedical Research, Inc.� POC:� Lead Subcontracts Administrator Jo Brown at jo.brown@nih.gov Response Dates:� Vendors Request for Proposal � Up to Monday, March 27, 2023.� Solicitation/RFP will be distributed upon request Questions Due; Monday, March 11, 2023� 10:00 AM EST Proposals Due by Tuesday March 28,2023, at 3:00 PM Anticipated Award date; by mid-July
- Web Link
-
SAM.gov Permalink
(https://sam.gov/opp/4a615103c939447f89a0f03cd52bc5a9/view)
- Record
- SN06577633-F 20230202/230131230106 (samdaily.us)
- Source
-
SAM.gov Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's SAM Daily Index Page |